PBM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PB

Mkt Cap

$16.1M

Volume

25.45K

Loading chart

PB

PBMPsyence Biomedical Ltd. Common Shares

PBM

Pay with—

Available Balance0.00

PB

Mkt Cap

$16.5M

Volume

25.45K

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity InvestmentPsyence Biomedical Ltd. (Nasdaq: PBM) announced that PsyLabs has exercised its put option rights, resulting in a Share-for-Share Exchange where Psyence will issue 1,146,159 common shares valued at $5 million to acquire 2,900 PsyLabs shares. Following the transaction, PsyLabs will own approximately 49.98% of Psyence BioMed. The deal is expected to close on February 25, 2026, and aims to strengthen supply chain security for pharmaceutical-grade psychedelic compounds as the company advances its clinical programs.GlobeNewswire Inc. · Feb 20, 2026

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization PathwayPsyence BioMed's board has ratified a put option agreement with PsyLabs, a leading pharmaceutical-grade psychedelic manufacturer. The agreement grants PsyLabs the right to require Psyence to make further equity investments while securing reliable supply of pharmaceutical-grade psychedelics for clinical and commercial programs. The structure preserves Psyence's near-term financial flexibility while advancing its development pathway.GlobeNewswire Inc. · Feb 13, 2026

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock SplitPsyence Biomedical Ltd. (Nasdaq: PBM) announced that its 1-for-6.25 reverse stock split will become effective on February 2, 2026, after being delayed from its original January 20 date. The consolidation will reduce outstanding shares from 6,388,604 to 1,022,177. The company's shares will continue trading under the symbol 'PBM' with a new CUSIP number.GlobeNewswire Inc. · Jan 28, 2026

Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026Psyence Biomedical Ltd. (Nasdaq: PBM) announced the adjournment of its annual and special shareholder meeting originally scheduled for January 22, 2026, to February 12, 2026, due to failure to achieve the requisite quorum. The company is working with proxy agents to ensure sufficient shareholder participation at the rescheduled meeting.GlobeNewswire Inc. · Jan 22, 2026

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity SciencePsyence BioMed advanced its Phase IIb clinical trial for psilocybin-assisted psychotherapy in palliative care, secured nature-derived psilocybin and ibogaine supply, and positioned itself as a leader in longevity science research.GlobeNewswire Inc. · Dec 9, 2025

Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On InvestmentPsyence BioMed made a $3.5 million follow-on investment in PsyLabs, a leading producer of psychedelic pharmaceutical ingredients, to secure a sustainable and ethical supply chain for its clinical research programs in mental health therapies.GlobeNewswire Inc. · Nov 3, 2025

US Stocks To Open Lower As Traders Brace For 'Triple Witching' Hour: Analyst Says End Of The Year Recovery 'Would Not Surprise Anyone'U.S. stock futures declined ahead of the 'Triple Witching' hour, with the market expected to see the expiry of about $6.6 trillion options. Analysts have mixed views on the market's recovery by the end of the year.Benzinga · Dec 20, 2024

Psyence Biomedical Announces Closing of Previously Announced Acquisition of Psyence Group's Stake in PsyLabsPsyence Biomedical has acquired an 11.13% stake in PsyLabs, a company focused on the cultivation and production of psychedelic active pharmaceutical ingredients. The acquisition is expected to benefit Psyence Biomedical's pipeline of psychedelic-based therapeutics.Benzinga · Oct 31, 2024

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabsPsyence Biomed has entered into an agreement to acquire an 11.13% stake in PsyLabs, a company focused on the production of psychedelic active pharmaceutical ingredients. This acquisition will strengthen Psyence Biomed's relationship with PsyLabs and provide access to state-of-the-art cultivation and production capabilities.Benzinga · Sep 19, 2024

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer ClairvoyantPsyence Biomed has signed a conditional binding term sheet to acquire Clairvoyant, a clinical-stage developer of psilocybin-based therapeutics. Clairvoyant is currently executing a Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential treatment for Alcohol Use Disorder (AUD), with topline data expected in early 2025.Benzinga · Sep 6, 2024

to start trading

PB

PBMPsyence Biomedical Ltd. Common Shares

PBM

Pay with—

Available Balance0.00

Your PositionYou don't own any PBM yet.

Related Tickers

Earnings